KPV Peptide Benefits and Side Effects: Research Data
What cell and animal studies report on KPV, why there is no human evidence yet, what FDA found on safety in 2026, and where KPV stands with regulators.
Update History ▾
Research-use-only framing applied throughout in line with Remy editorial standards.
The KPV peptide benefits discussed online (calming inflammation, gut health in inflammatory bowel disease, and skin inflammation) come from cell culture and animal studies. There is no human evidence that KPV helps any condition. In mouse colitis models KPV reduced intestinal inflammation, and in human cells it suppressed NF-κB inflammatory signalling.[1][2][3]
KPV side effects in people are unknown, not absent. FDA found no clinical studies or human exposure data for KPV by any route, concluded that its potential safety risks in humans are unknown, and said it cannot rule out immune reactions.[4] No KPV trial is registered.[5] KPV is not an approved medicine, and Remy Research supplies it for in-vitro laboratory research only.
What Is the KPV Peptide?
KPV is a tripeptide of three amino acids: lysine, proline and valine (Lys-Pro-Val). It is the C-terminal end, residues 11 to 13, of alpha melanocyte stimulating hormone (α-MSH), a peptide hormone involved in skin pigmentation and in damping immune responses.[6][7] Reviews describe it as a candidate anti-inflammatory fragment with a cleaner pigment side-effect profile than full α-MSH.[6]
KPV is not a dietary supplement, is not one of the approved anti-inflammatory drugs, and has no approved medical use. FDA reviewed it in 2026 and found no information on any KPV product given to people.[4]
How KPV Works in Intestinal Epithelial Cells and the Immune System
Two routes have been described, and they may both apply. In human gut epithelial cells (colonic cell lines) and T cells, nanomolar KPV inhibited the NF-κB and MAPK inflammatory pathways and reduced pro-inflammatory cytokine production. It acts through PepT1, a transporter expressed in epithelial and immune cells that normally moves small peptides from food.[1] In human bronchial epithelial cells, KPV entered the nucleus, stabilised the NF-κB inhibitor IκBα and blocked the nuclear import of the p65 subunit, cutting IL-8 secretion. That effect did not depend on melanocortin receptors.[3]
The result in these models is lower inflammatory gene expression along the main inflammatory pathways, rather than broadly suppressing the immune system. Whether the same happens in human tissue in the body has not been tested.
Potential Benefits Studied So Far
| Claimed benefit | What was reported | Evidence type |
|---|---|---|
| Gut inflammation | Less colitis in DSS, TNBS and T-cell transfer mouse models | Animal |
| Inflammatory signaling | Lower NF-κB activity and IL-8 in human cell lines | Cell culture |
| Skin inflammation | Less fine-dust damage and inflammation in keratinocytes | Cell culture |
| Antimicrobial | Inhibited S. aureus and C. albicans in culture | Laboratory assay |
| Systemic inflammation | Lower cytokines in blood samples treated outside the body | Ex-vivo human blood |
| Oral delivery | A prodrug form reached inflamed colon and lung in mice | Animal |
Intestinal Inflammation and Inflammatory Bowel Disease: Animal Studies
Most KPV research is on intestinal inflammation of the gastrointestinal tract, the setting of inflammatory bowel disease, a chronic inflammatory disease. In mice with DSS- and TNBS-induced colitis, oral administration of KPV in drinking water reduced disease activity, colonic inflammation scores and inflammatory cells in the gut lining, and cut a marker of neutrophil infiltration by about half. In these models KPV lowered inflammation in the colon, but reducing inflammation in mice is not the same as treating colitis in people.[1] A second group found earlier recovery and less inflammation in two colitis models, including one driven by T cells, and the effect persisted in mice lacking a working MC1R receptor.[2] Reviews of the melanocortin system in ulcerative colitis and Crohn’s disease note that this evidence comes from murine models.[8]
A 2026 study built an oral prodrug, proKPV, that releases KPV where inflammation is present. In mouse colitis it reached the colon at higher levels than free KPV, and it also reduced lung inflammation in mice with acute lung injury.[9]
Pro-Inflammatory Cytokines: IL-1β, IL-6 and IFN-γ
In the same experimental colitis work, KPV treatment lowered colonic mRNA for the inflammatory cytokines IL-1β, IL-6, IL-12 and IFN-γ after DSS, and IL-1β, IL-6, TNF-α and IFN-γ after TNBS.[1] These are the inflammatory markers behind most claims about KPV and systemic inflammation, but they were measured in mouse colon.
Anti-Inflammatory Effects in Human Bronchial Epithelial Cells
The clearest human-cell data come from airway cells. In human bronchial epithelial cells, KPV caused a dose-dependent fall in NF-κB activity and in the secretion of IL-8 and eotaxin, two inflammatory markers, without needing a melanocortin receptor.[3] That is an anti-inflammatory effect in a dish, not evidence on chronic inflammation in a patient.
Skin, Immune Cells and Inflammatory Responses
In keratinocytes exposed to fine dust, KPV reduced cell death and inflammation by lowering oxidative stress and MAPK/NF-κB signalling.[10] In macrophages it reduced foam cell formation and inflammatory responses.[11] Older laboratory work on its antimicrobial properties found that α-MSH and KPV inhibited colony formation of the bacterium Staphylococcus aureus and reduced the viability of Candida albicans in culture.[12] In blood samples from people with HIV, treated outside the body, melanocortin peptides lowered the production of inflammatory cytokines.[13] These are useful clues about its anti-inflammatory properties in inflammatory skin conditions and other inflammatory diseases, but every one of them is a laboratory finding.
Human Evidence: Gut Symptoms and Immune Balance
There is none for KPV as a treatment. A ClinicalTrials.gov search on October 27, 2026 returned no KPV studies at any phase.[5] FDA’s 2026 briefing found no clinical studies or human exposure data by any route and a lack of evidence to evaluate KPV for its nominated uses, wound healing and inflammatory conditions.[4] Claims made for KPV peptide therapy, such as relieving gut symptoms, irritable bowel syndrome, histamine intolerance or autoimmune flares, or restoring immune balance in chronic inflammatory conditions, are not supported by any published clinical evaluation.
KPV Side Effects and Safety Concerns
- Unknown human safety. FDA stated that because no human exposure data exist, the potential safety risks of KPV in humans are unknown.[4]
- Immune reactions. FDA noted that peptides such as KPV can provoke an immunogenic response, and that there are insufficient data to conclude KPV does not carry that risk, including from aggregates.[4]
- Impurities. Peptide-related and synthesis-related impurities form part of the risk profile of any peptide, including KPV.[4]
- No adverse-event record. With no human studies, there is no list of side effects to report; an absence of reports is not evidence of safety.
FDA proposed not adding KPV to the list of substances compounding pharmacies may use.[4]
Is KPV FDA Approved?
- FDA approval. No. KPV is not an approved drug in the United States.[4]
- Compounding. KPV left FDA’s Category 2 safety-risk list because its nomination was withdrawn, not through an FDA reversal.[14] On July 23, 2026 FDA’s advisory committee voted to recommend adding it to the compounding list, against the advice of FDA’s reviewers; the vote is non-binding.[15][4]
- Sport. KPV is not named on WADA’s Prohibited List, but class S0 covers substances with no approval for human therapeutic use, and for 2027 WADA warns that peptides not named on the List may still be prohibited.[16]
- UAE. KPV is not a registered medicine. Remy Research sells it for in-vitro laboratory research only, not for human or veterinary use.
KPV vs Other Peptides
KPV is often compared with BPC-157 and GHK-Cu. All three are studied for inflammation or tissue repair, but they act differently: KPV is a melanocortin fragment that dampens NF-κB signalling, BPC-157 is a 15-amino-acid gastric peptide studied for tissue repair, and GHK-Cu is a copper-binding tripeptide studied mainly in skin. See KPV vs BPC-157 vs GHK-Cu and BPC-157 benefits and side effects.
What KPV Research Does Not Yet Give You
- Any human trial. No KPV study is registered, and none has been published.[5][4]
- A settled mechanism. PepT1 uptake, nuclear blockade of NF-κB and melanocortin-related effects have each been proposed.[1][3][2]
- Human pharmacokinetics. How much KPV reaches tissue by any route in people is not known; the oral prodrug work is in mice.[9]
These gaps are not arguments against KPV research. They are arguments against overselling it.
KPV for Laboratory Research
Remy Research supplies KPV for in-vitro research as the KPV 10mg research vial and the Genovare KPV 30mg AQ pen. Each product page carries its batch testing details. For the full mechanism and animal-model record, read the KPV tripeptide research review.
Our Research Standards
This article prioritizes primary literature, trial registries and regulator records, and keeps cell, animal and human evidence apart. Where the human record is empty, we say so directly. No therapeutic, dosing or administration guidance is given. Read our editorial policy →
KPV Benefits and Side Effects FAQ
What is KPV peptide used for?
What are the benefits of KPV peptide?
What are the side effects of KPV?
They are unknown. FDA found no human exposure data for KPV, concluded its safety risks in humans are unknown, and could not rule out immune reactions.[4]
Is KPV safe?
Its safety in people has not been studied. The absence of reported side effects reflects the absence of human studies, not proof of safety.[4]
What does KPV do in the body?
Is KPV FDA approved?
Is KPV the same as alpha-MSH?
No. KPV is the last three amino acids (residues 11 to 13) of alpha melanocyte stimulating hormone, studied because it kept much of its anti-inflammatory activity.[6]
Is KPV banned in sport?
It is not named on WADA’s Prohibited List, but WADA warns that unnamed peptides without human therapeutic approval may fall under class S0.[16]
Sources
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. doi: 10.1053/j.gastro.2007.10.026 · PMID: 18061177 ↩
- Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. doi: 10.1002/ibd.20334 · PMID: 18092346 ↩
- Land SC. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. Int J Physiol Pathophysiol Pharmacol. 2012;4(2):59-73. PMID: 22837805 ↩
- U.S. Food and Drug Administration. FDA Briefing Document: KPV-Related Bulk Drug Substances (KPV (free base) and KPV acetate), dated May 12, 2026. Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026. fda.gov/media/193346 ↩
- ClinicalTrials.gov search for KPV or “Lys-Pro-Val”, run October 27, 2026 (0 studies). clinicaltrials.gov ↩
- Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008;29(5):581-602. doi: 10.1210/er.2007-0027 · PMID: 18612139 ↩
- National Center for Biotechnology Information. PubChem Compound Summary for CID 125672, MSH (11-13) (Lys-Pro-Val). pubchem.ncbi.nlm.nih.gov/compound/125672 ↩
- Gravina AG, Pellegrino R, Durante T, et al. The melanocortin system in inflammatory bowel diseases: insights into its mechanisms and therapeutic potentials. Cells. 2023;12(14):1889. doi: 10.3390/cells12141889 · PMID: 37508552 ↩
- Cheng J, Wu P, Li C, et al. Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers. Sci Adv. 2026;12(3). doi: 10.1126/sciadv.aea2989 · PMID: 41533788 ↩
- Sung J, Ju SY, Park S, Jung WK, Je JY, Lee SJ. Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway. Tissue Cell. 2025;95:102837. doi: 10.1016/j.tice.2025.102837 ↩
- Bai JS, Kim RW, Li Y, Jung WK, Je JY, Lee SJ. Lysine-Proline-Valine attenuates oxidized low-density lipoprotein-induced foam cell formation and inflammatory responses in RAW264.7 macrophages. Tissue Cell. 2026;104(Pt 3):104036. doi: 10.1016/j.tice.2026.104036 · PMID: 42854645 ↩
- Cutuli M, Cristiani S, Lipton JM, Catania A. Antimicrobial effects of alpha-MSH peptides. J Leukoc Biol. 2000;67(2):233-239. doi: 10.1002/jlb.67.2.233 · PMID: 10670585 ↩
- Catania A, Garofalo L, Cutuli M, Gringeri A, Santagostino E, Lipton JM. Melanocortin peptides inhibit production of proinflammatory cytokines in blood of HIV-infected patients. Peptides. 1998;19(6):1099-1104. doi: 10.1016/s0196-9781(98)00055-2 · PMID: 9700761 ↩
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2; section “Bulk drug substances nominated but withdrawn”). Updated April 22, 2026. fda.gov ↩
- Reuters. FDA advisers back first four of seven unapproved peptides under review for looser rules. July 23, 2026. reuters.com ↩
- World Anti-Doping Agency. 2027 Prohibited List: Summary of Major Modifications and Explanatory Notes (dated August 17, 2026; List in force January 1, 2027). wada-ama.org ↩
For catalog details, see the KPV 10mg research vial and the Genovare KPV 30mg AQ pen. For editorial standards, continue to the editorial policy.